Related Experiment Video
Updated: Oct 1, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Role of Virus-Directed Therapy in Soft Tissue Sarcoma
Hira Chaudhary1, Sandra D'Angelo2
1Department of Sarcoma, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering, 1275 York Ave, New York, NY, 10065, USA.
Opinion Statement:
Bone and soft tissue sarcoma are rare cancers of mesenchymal origin with the characteristics of heterogeneity and diversity that account for less than 1% of solid malignant cancers. Conventional chemotherapy remains standard of care with response rates of 10-15% that are usually dependent on histologic subtype as some subtypes are chemotherapy resistant. There remains a large unmet clinical need for new and novel options promoting the development of promising therapeutic options such as immunotherapy. With more than 80 different subtypes, the heterogeneity of sarcoma requires thoughtful clinical trial design. In the sarcoma field, recent breakthroughs have occurred in the context of histology-specific approach based on underlying tumor biology. To that end, immunotherapy approaches will need to take a similar approach. Oncolytic viruses (OVs) have emerged as a promising treatment for many solid tumors and shown encouraging results in sarcoma. This review mainly focuses on collective clinical data highlighting the role of OVs as immunotherapy being used in soft tissue sarcoma (STS) and bone sarcomas. Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy or targeted therapies may yield increased potency, improve antitumor efficacy of oncolytic virotherapy, and offer a new prospect for the treatment of sarcoma.
Insights
Oncolytic viruses (OVs) show promise as immunotherapy for rare bone and soft tissue sarcomas. Combining OVs with other therapies may improve treatment efficacy for these diverse cancers.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Bone and soft tissue sarcomas are rare, heterogeneous cancers with poor response to conventional chemotherapy.
- A significant unmet need exists for novel therapeutic strategies in sarcoma treatment.
- Recent advances in sarcoma treatment emphasize histology-specific approaches based on tumor biology.
Purpose of the Study:
- To review clinical data on oncolytic viruses (OVs) as an immunotherapy for soft tissue sarcoma (STS) and bone sarcomas.
- To highlight the potential of OVs in addressing the heterogeneity of sarcoma.
- To explore combination strategies to enhance OV efficacy in sarcoma treatment.
Main Methods:
- Review of collective clinical data on oncolytic virus therapy in sarcoma.
- Analysis of OV application in soft tissue sarcoma (STS) and bone sarcomas.
- Exploration of potential combination therapies with OVs.
Main Results:
- Oncolytic viruses (OVs) have demonstrated encouraging results in treating various solid tumors, including sarcomas.
- The heterogeneity of sarcoma necessitates tailored immunotherapy approaches, aligning with OV potential.
- Preliminary data suggests OVs are a promising immunotherapy option for soft tissue and bone sarcomas.
Conclusions:
- Oncolytic viruses represent a promising immunotherapy avenue for soft tissue and bone sarcomas.
- Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy, or targeted therapies may enhance antitumor efficacy.
- Further research and clinical trial design focusing on histology-specific approaches are crucial for optimizing OV-based sarcoma treatment.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Subviral Agents

